Competition Law and Genomic Infrastructure Monopolies

1. Introduction

Genomic infrastructure refers to the technological, informational and physical systems necessary to generate, process, store, interpret and commercialise genomic information. It includes:

• DNA and RNA sequencing platforms;
• high-throughput sequencing instruments;
• genomic databases and reference datasets;
• biobanks and sample repositories;
• bioinformatics and genomic-analysis software;
• cloud infrastructure for genomic computation;
• genetic testing laboratories;
• population-scale genomic databases;
• genomic-data interoperability standards and APIs;
• variant-classification databases;
• diagnostic pipelines and laboratory networks; and
• essential patents, reagents and sequencing technologies.

A genomic infrastructure monopoly arises when one undertaking or a small group of undertakings obtains durable control over an infrastructure layer that competitors cannot realistically reproduce or bypass.

The competition problem is particularly significant because genomic infrastructure can create vertical leverage. A company controlling sequencing technology may also participate in genetic testing, diagnostics, drug discovery or genomic databases. It may therefore have the ability and incentive to disadvantage downstream competitors.

The most important modern illustration is the Illumina–GRAIL litigation. The FTC treated Illumina's control of next-generation sequencing technology as potentially capable of affecting competition in the downstream multi-cancer early-detection market. The European Union likewise scrutinised the transaction under merger-control principles.

2. Why Genomic Infrastructure Is Different

Genomic infrastructure can produce several characteristics associated with monopoly or essential-facility problems.

A. Very high entry costs

Sequencing platforms require:

• advanced chemistry;
• optics;
• semiconductor technology;
• specialised software;
• laboratories;
• patents;
• substantial R&D expenditure; and
• large-scale manufacturing.

The FTC's materials in the Illumina–PacBio matter described entry into next-generation sequencing as time-consuming and extremely difficult, involving substantial scientific, legal and commercial barriers.

B. Network effects

A sequencing platform becomes more valuable when:

• more laboratories use it;
• more researchers develop protocols around it;
• more software supports it;
• more genomic datasets are generated in compatible formats; and
• more diagnostic companies validate their tests against it.

This can create a feedback loop:

More users → more data → more validation → more applications → more users.

C. Switching costs

A laboratory may have invested millions in:

• sequencing instruments;
• reagents;
• staff training;
• software;
• validation;
• regulatory approvals; and
• accumulated historical datasets.

Switching to another platform can therefore be commercially difficult even if an alternative technology exists.

D. Data advantages

A genomic infrastructure provider can potentially accumulate enormous datasets.

The competitive advantage may therefore come not merely from owning machines but from controlling:

machines + data + algorithms + standards + downstream applications.

3. Relevant Competition-Law Framework

Genomic infrastructure monopolies can be examined through several doctrines.

A. Abuse of dominance

A dominant genomic infrastructure provider may abuse its position through:

• discriminatory access;
• refusal to supply;
• exclusionary licensing;
• tying;
• bundling;
• loyalty rebates;
• exclusive agreements;
• discriminatory API access;
• interoperability restrictions;
• predatory pricing;
• discriminatory technical standards; or
• leveraging infrastructure dominance into downstream markets.

B. Essential-facilities principles

The essential-facilities doctrine becomes relevant where an infrastructure is:

1. indispensable;
2. practically impossible to duplicate;
3. controlled by a dominant undertaking;
4. necessary for effective downstream competition; and
5. capable of being supplied without undermining legitimate business interests.

However, mere usefulness does not make genomic infrastructure an essential facility.

Competition authorities and courts generally distinguish between:

“important infrastructure”

and

“legally indispensable infrastructure.”

That distinction is crucial.

4. Genomic Infrastructure Monopoly: Major Competition Concerns

4.1 Sequencing-platform foreclosure

Suppose Company A controls 80–90% of sequencing instruments and simultaneously develops genomic cancer diagnostics.

It could theoretically:

• restrict access to its machines;
• impose discriminatory pricing;
• delay technical support;
• limit compatibility;
• restrict reagent supply;
• obtain confidential information from downstream rivals; or
• favour its own diagnostic products.

The infrastructure monopoly would therefore become a vertical foreclosure mechanism.

5. Six Important Case Laws

Case 1 — FTC v. Illumina / GRAIL

Federal Trade Commission and United States competition litigation; 2021–2024

This is the most directly relevant modern case.

Illumina was a dominant supplier of next-generation DNA sequencing platforms, while GRAIL developed a multi-cancer early-detection test using DNA sequencing.

The FTC argued that Illumina's acquisition of GRAIL could give Illumina the ability and incentive to disadvantage competing developers of multi-cancer early-detection tests because those companies depended on Illumina's sequencing technology.

The FTC ultimately ordered divestiture in 2023. The Fifth Circuit subsequently found substantial evidence supporting the Commission's determination but remanded the matter concerning the treatment of Illumina's rebuttal evidence. Illumina then announced that it would divest GRAIL.

Competition-law significance

The case demonstrates the importance of vertical infrastructure concentration.

The concern was not simply:

“Illumina is large.”

The deeper issue was:

Could control over an upstream genomic infrastructure layer give Illumina the ability and incentive to impair competition in a downstream innovation market?

Principle

A merger involving genomic infrastructure must therefore consider:

Upstream sequencing power + downstream genomic innovation = potential foreclosure risk.

Case 2 — Illumina, Inc. v. European Commission / GRAIL

Court of Justice of the European Union, Joined Cases C-611/22 P and C-625/22 P, 2024

The European Commission also examined the Illumina–GRAIL transaction.

The case concerned, among other things, whether a national competition authority that lacked jurisdiction to review the transaction under its own national merger-control rules could make an Article 22 referral enabling Commission review.

The CJEU delivered judgment on 3 September 2024.

Competition-law significance

The case is particularly important for genomic infrastructure because potentially problematic acquisitions may occur below traditional merger-notification thresholds.

Genomic startups can have:

• low current revenue;
• highly valuable technology;
• enormous future competitive significance.

Consequently, conventional turnover thresholds may fail to capture acquisitions involving nascent genomic infrastructure competitors.

Principle

Competition authorities may need to examine:

future competitive significance rather than merely present revenue.

Case 3 — FTC v. Illumina / Pacific Biosciences

FTC administrative proceeding, 2019–2020

Illumina proposed acquiring Pacific Biosciences (PacBio), another developer of DNA sequencing technology.

The FTC alleged that Illumina was seeking to maintain its position in the U.S. next-generation sequencing market by eliminating PacBio as a nascent competitive threat. The transaction was abandoned in January 2020.

FTC materials described Illumina as holding a dominant position in the U.S. NGS market and identified substantial barriers to entry.

Competition-law significance

This case shows that genomic infrastructure competition can be endangered before the challenger becomes a mature competitor.

A dominant infrastructure provider does not necessarily have to eliminate an established competitor. Acquisition of a technologically promising challenger may itself raise competition concerns.

Principle

Competition law can protect:

• actual competition;
• potential competition; and
• innovation competition.

This is particularly important in rapidly developing genomic technology.

Case 4 — Element Biosciences v. Illumina

U.S. District Court, Northern District of California, 2026

Element Biosciences brought competition-law claims against Illumina concerning the next-generation DNA sequencing instrument market.

Element alleged, among other things, exclusionary conduct involving:

• punitive pricing;
• exclusive arrangements;
• below-cost pricing;
• bundled and direct discounts; and
• alleged disparagement.

In May 2026, the District Court granted Illumina's motion to dismiss, while allowing amendment. The allegations therefore should not be treated as established facts or a final finding of unlawful monopolisation.

Competition-law significance

The case illustrates the type of conduct that can become relevant when a dominant genomic infrastructure company faces a new technological entrant.

Potential theories include:

• monopolisation;
• exclusive dealing;
• predatory pricing;
• bundling;
• foreclosure of customers;
• raising rivals' costs; and
• exclusionary conduct.

Principle

Dominance itself is not necessarily unlawful. The critical question is whether the dominant undertaking uses exclusionary conduct that harms the competitive process.

Case 5 — IMS Health GmbH & Co. OHG v NDC Health

CJEU, Case C-418/01, 2004

This is not a genomic case, but it is highly relevant to genomic databases and infrastructure.

IMS Health controlled a commercially significant pharmaceutical-sales data structure. A competitor sought access to the structure, and the dispute raised the circumstances in which refusal to license intellectual-property-protected infrastructure could constitute an abuse of dominance.

The CJEU developed stringent conditions for compulsory access.

Competition-law significance

The case provides a useful framework for genomic databases.

Imagine a company controls:

• a unique population-genomics database;
• an indispensable variant database;
• a reference genomic dataset; or
• a unique disease-genomics dataset.

A competitor might argue that it cannot compete without access.

IMS Health indicates that compulsory access should not automatically follow from the infrastructure's importance.

Relevant considerations

A refusal becomes more problematic where:

1. access is indispensable;
2. duplication is effectively impossible;
3. refusal eliminates effective competition;
4. there is no objective justification; and
5. access is necessary for a new or distinct product/service.

Principle

Control over intellectual property does not automatically create an obligation to license, but exceptional circumstances can justify access remedies.

This is particularly important for genomic databases.

Case 6 — Bronner v Mediaprint

CJEU, Case C-7/97, 1998

Although unrelated to genomics, Bronner is a foundational European essential-facilities case.

The dispute concerned access to a newspaper distribution system.

The CJEU adopted a demanding standard for treating infrastructure as indispensable.

Application to genomics

Consider a hypothetical genomic sequencing platform.

A competitor would generally need to demonstrate more than:

“This sequencing platform is the most convenient.”

It would need to establish something closer to:

“There is no realistic alternative and duplication is not economically or technically feasible.”

Genomic application

The doctrine could become relevant to:

• national genomic reference databases;
• unique biobank infrastructure;
• specialised sequencing facilities;
• genomic cloud infrastructure;
• indispensable interoperability systems; and
• unique variant-classification platforms.

Principle

Essentiality must be demonstrated, not assumed merely because infrastructure is commercially important.

6. Microsoft and Interoperability Infrastructure

Case 7 — Microsoft Corp. v Commission

General Court of the European Union, T-201/04, 2007

Microsoft concerned interoperability information and the ability of a dominant undertaking to restrict rivals' access to technical information necessary for interoperability.

The case is extremely relevant by analogy to genomic infrastructure.

Genomic equivalent

Imagine a dominant sequencing company controlling:

• proprietary genomic file formats;
• APIs;
• interoperability specifications;
• machine-learning interfaces;
• sequencing metadata;
• laboratory information interfaces.

If competitors cannot realistically interoperate with the dominant system, the infrastructure provider could potentially extend its dominance into adjacent markets.

Potential genomic foreclosure

Sequencing platform → proprietary format → software lock-in → diagnostic lock-in

This can transform technological compatibility into a competitive barrier.

Principle

Interoperability can itself have substantial competition significance where control over technical interfaces gives a dominant undertaking the ability to restrict downstream competitors.

7. Aspen Skiing as an Exclusionary-Conduct Analogy

Case 8 — Aspen Skiing Co. v Aspen Highlands Skiing Corp.

U.S. Supreme Court, 1985

The Supreme Court considered whether a dominant business's termination of an established cooperative arrangement could constitute exclusionary conduct.

The case is important because it demonstrates that refusal to cooperate is not automatically lawful or unlawful.

Genomic application

Suppose a dominant sequencing provider previously:

• supplied reagents to competitors;
• provided technical access;
• permitted interoperability;
• shared certain infrastructure; or
• participated in a common genomic platform.

If it suddenly terminated access specifically to exclude a rival, the historical pattern of cooperation could become relevant.

Principle

A refusal to deal can raise competition concerns where the circumstances demonstrate exclusionary rather than legitimate competitive conduct.

8. Competition Problems Across the Genomic Infrastructure Stack

9. Data Concentration as a Genomic Monopoly

Genomic infrastructure monopolies increasingly involve data rather than physical infrastructure.

Suppose one company controls the world's largest commercially usable dataset concerning a particular disease.

The competitive advantage may arise from:

Data volume → better model → better predictions → more customers → more data.

This creates a genomic data feedback loop.

Competitors may then face difficulty entering because they cannot reproduce the dataset.

Competition law may therefore need to examine:

• exclusive data agreements;
• discriminatory data access;
• data portability;
• interoperability;
• exclusive biobank arrangements;
• data aggregation through mergers;
• self-preferencing;
• tying genomic data to sequencing services; and
• discriminatory API access.

10. Vertical Integration

One of the most important risks is vertical integration.

Consider:

Sequencing company

↓

Genomic database

↓

Bioinformatics software

↓

Genetic diagnostic testing

↓

Precision medicine

A single undertaking controlling several layers could potentially disadvantage competitors at multiple stages.

For example, it could theoretically:

• charge competitors more for sequencing;
• give its own diagnostics preferential access;
• restrict competitors' access to data;
• prioritise its own software;
• impose incompatible technical standards; or
• bundle sequencing with downstream services.

This is the ecosystem foreclosure problem.

11. Merger-Control Concerns

Traditional merger control can underestimate genomic infrastructure transactions.

A startup may have:

• minimal revenue;
• few customers;
• no profitable product;

but possess:

• unique genomic data;
• breakthrough sequencing technology;
• valuable patents;
• an innovative algorithm;
• a large research network; or
• the potential to become a significant infrastructure competitor.

Therefore, merger analysis should consider:

1. Nascent competition

Could the target become a meaningful future competitor?

2. Innovation competition

Will the acquisition reduce independent R&D?

3. Data concentration

Will the transaction combine uniquely valuable genomic datasets?

4. Vertical foreclosure

Will the acquirer control an infrastructure bottleneck?

5. Ecosystem effects

Will the combined entity control several complementary genomic services?

12. Essential-Facility Analysis for Genomic Databases

A genomic database is more likely to raise essential-facility concerns where:

A. Indispensability

No commercially realistic alternative database exists.

B. Non-duplicability

Creating an equivalent database would require decades of data collection or impossible access to particular samples.

C. Competitive elimination

Without access, competitors cannot effectively operate.

D. Lack of justification

The infrastructure owner lacks a legitimate technical, security, privacy or commercial justification for refusal.

E. Feasible access

Access can be provided without undermining:

• privacy;
• cybersecurity;
• intellectual-property rights;
• data integrity;
• patient consent; or
• legitimate commercial interests.

13. Privacy and Competition Law Must Be Distinguished

Genomic data is exceptionally sensitive.

Therefore, competition law cannot simply require unrestricted access to genomic databases.

Access remedies may need to incorporate:

• informed consent;
• anonymisation/pseudonymisation;
• data-security requirements;
• purpose limitation;
• ethical governance;
• research restrictions;
• access auditing;
• intellectual-property protection; and
• cybersecurity safeguards.

Thus:

Competition-law access ≠ unrestricted disclosure of genomic information.

A competition remedy must coexist with data-protection and bioethics requirements.

14. Possible Anticompetitive Strategies

A genomic infrastructure monopolist could potentially engage in:

1. Exclusive dealing

Requiring laboratories to use only its sequencing technology.

2. Loyalty rebates

Discounts conditional upon purchasing most sequencing capacity from the incumbent.

3. Tying

Making genomic-analysis software available only with its sequencing equipment.

4. Bundling

Combining:

sequencing + cloud storage + analysis + diagnostics.

5. Refusal to supply

Denying competitors access to essential infrastructure.

6. Data discrimination

Providing the incumbent's downstream division with better data access.

7. API discrimination

Giving competitors slower, restricted or technically inferior API access.

8. Predatory pricing

Pricing sequencing instruments or services below an appropriate cost benchmark to eliminate entrants.

9. Interoperability restrictions

Making competing software difficult to integrate.

10. Acquisition of nascent competitors

Buying emerging genomic technologies before they become substantial competitive threats.

15. Remedies

Competition authorities could consider several remedies.

Structural remedies

• divestiture;
• separation of infrastructure and downstream operations;
• prohibition of certain acquisitions;
• business-unit separation.

The Illumina–GRAIL proceedings demonstrate that divestiture can become the remedy where vertical integration threatens competition.

Behavioural remedies

• non-discriminatory access;
• transparent pricing;
• interoperability obligations;
• API access;
• prohibition of exclusive agreements;
• data-portability requirements;
• firewall arrangements;
• licensing commitments.

Regulatory remedies

Governments could also establish:

• genomic interoperability standards;
• public genomic repositories;
• research-access frameworks;
• data-sharing protocols;
• open technical standards; and
• independent genomic infrastructure governance.

16. Indian Competition-Law Perspective

In India, genomic infrastructure monopolies could principally be examined under the Competition Act, 2002, particularly:

Section 4

Prohibits abuse of dominant position.

Potentially relevant forms include:

• unfair or discriminatory conditions;
• unfair or discriminatory prices;
• denial of market access;
• limiting technical or scientific development;
• tying;
• leveraging dominance into another relevant market.

Section 5

Merger-control provisions become relevant to combinations involving genomic companies.

Section 20

The Competition Commission of India can examine combinations and relevant competition concerns.

Section 27

Provides remedial powers where contravention is established.

The relevant-market analysis would be particularly important.

For example, the CCI might need to distinguish between:

• DNA sequencing instruments;
• sequencing services;
• genomic databases;
• genetic diagnostic services;
• bioinformatics;
• genomic cloud services; and
• genomic data markets.

A broad market definition could conceal infrastructure bottlenecks, while an excessively narrow definition could artificially manufacture dominance.

17. Relevant-Market Problem

Genomic markets can be difficult to define because products evolve rapidly.

A sequencing platform may compete with:

• another sequencing platform;
• a sequencing service;
• cloud-based genomic processing;
• an entirely different sequencing technology.

Therefore, competition authorities may need to examine:

• substitutability;
• switching costs;
• interoperability;
• technological performance;
• accuracy;
• throughput;
• price;
• regulatory validation;
• installed-base effects; and
• innovation pipelines.

The Illumina proceedings demonstrate how technological characteristics and dependence on sequencing platforms can become central to defining competitive relationships.

18. Key Doctrinal Synthesis

The major cases can be organised as follows:

The first four are directly connected to genomic or sequencing competition; the latter cases provide general antitrust doctrines that can be applied to genomic infrastructure. That distinction is important because there is still a relatively limited body of reported judicial decisions specifically addressing genomic databases as essential facilities.

19. Emerging Concept: Genomic Infrastructure as a Bottleneck

The most important future competition issue is likely to be the development of genomic bottlenecks.

A bottleneck exists where a company controls a resource through which competitors must pass.

For example:

Genomic samples
↓
Sequencing infrastructure
↓
Genomic database
↓
AI analysis
↓
Diagnostic platform
↓
Precision medicine

If one undertaking controls multiple layers, traditional single-market analysis may underestimate its competitive significance.

The more appropriate approach may therefore be an ecosystem analysis.

20. Conclusion

Competition law concerning genomic infrastructure monopolies is ultimately concerned with preventing control over a technological or informational bottleneck from being transformed into durable ecosystem power.

The principal risks are:

1. sequencing-platform dominance;
2. genomic-data concentration;
3. database access discrimination;
4. interoperability restrictions;
5. vertical foreclosure;
6. exclusive dealing;
7. tying and bundling;
8. acquisition of nascent genomic competitors;
9. innovation suppression; and
10. control over indispensable genomic infrastructure.

The Illumina–GRAIL and Illumina–PacBio proceedings are particularly significant because they demonstrate that competition authorities may scrutinise not only existing market shares but also control of upstream genomic infrastructure, nascent competition and future innovation.

The essential-facilities cases such as IMS Health and Bronner, together with Microsoft on interoperability, provide the doctrinal tools for analysing when genomic databases, APIs, sequencing platforms or other infrastructure might become competitively indispensable.

The central legal question can therefore be expressed as:

When does control over genomic infrastructure constitute legitimate technological success, and when does the exercise or extension of that control unlawfully restrict the competitive process?